Market Pulse57Neutral

Can-Fite BioPharma Ltd.Opportunity Rank #286(CANF) Intrinsic Value & DCF Analysis (2026)

Sector: Healthcare

Current Price

$3.22

Last updated: Jul 15, 2026

Price vs Intrinsic Value

$3.22
Price
-$12.66
Intrinsic Value
Overvalued by 493%MOS: -$10.13

Fundamental Score

46/100
Bearish

Weighted across 6 signals

Narrative Score

55/100
Improving

-1 vs previous

Trend Score

40/100
Weak

As of 2026-07-14

The intrinsic value of Can-Fite BioPharma Ltd. (CANF) is estimated at $-12.66 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $3.22, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -16.17% long-term growth rate and a 10.00% discount rate (calculated: 7.74%), reflecting expected future free cash flow and cost of capital.

The intrinsic value of Can-Fite BioPharma Ltd. (CANF) is estimated at $-12.66 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $3.22, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a -16.17% long-term growth rate and a 10.00% discount rate (calculated: 7.74%), reflecting expected future free cash flow and cost of capital.

Valuation Details

-$12.66
▼ -493.17% downside
20% margin of safety: -$10.13
Years: 10Growth Rate: -16.17%
Want to create your own valuation? Create a free account.

Fundamental Details

46/100
BearishWeighted across 6 signals
DCF Discount
493.2% premium to price
0
FCF Yield
-516.5% trailing FCF yield
0
ROIC vs WACC
ROIC vs WACC unavailable
50
Net Debt / FCF
1.0x net debt to FCF
81
Buybacks
Share count flat
50
FCF CAGR (5Y)
32.5% 5Y FCF CAGR (adjusted)
100
Strengths: Net Debt / FCF, FCF CAGR (5Y). Concerns: DCF Discount, FCF Yield.

Narrative Details

55/100
Improving
-1 vs previousVs 6-Month Baseline:High (88th pct)Weighted across 4 recent drivers
Trend: StableConfidence: 60%Updated: 13h ago
Sources: 13 (10 News · 3 Analyst)
Drivers(last 30 days)
3 regulatory scrutiny+0.4
7 news sentiment+0.2
Analyst upgrades+0.0
2 analyst reiterations0.0

Trend Details

40/100
WeakAs of 2026-07-14309 daily bars used
Distance from 52-Week High-84.7%
6M Relative Strength vs SPY-30.5%
Price vs 21 EMA-1.9%
Price vs 21 EMA39 · -1.9%
Price vs 50 EMA40 · -1.9%
21 EMA vs 50 EMA49 · -0.1%
3M RS vs SPY53 · +0.7%
6M RS vs SPY3 · -30.5%
Distance from 52W High0 · -84.7%

Investment Coach

Updating... 34d ago
AVOIDConfidence: 89%
Thesis
Can-Fite BioPharma Ltd. is significantly overvalued with an estimated fair value 170% below its current price, supported by weak fundamentals and negative free cash flow yield. The company's returns are trailing its cost of capital, indicating poor financial performance and limited upside potential.
Key Risk
The primary risk is continued deterioration in financial performance, which could further depress valuation and shareholder returns.
Signals To Watch
  • Price moving to at least a mid-teens discount to fair value
  • Improvement in ROIC versus WACC spread
  • Meaningful positive shifts in the narrative score direction
Ask the Coach - Available with
Historical Growth Rates
Free Cash Flow- - -Trend CAGR (Adjusted): -16.24%5 Year CAGR (Adjusted): 13.70%

Free Cash Flow (in millions)

TTM2025202420232022202120202019201820172016201520142013201220112010
-$9-$9-$8-$8-$11-$10-$12-$11-$4-$10-$9-$5-$7-$9-$4-$5-$4

How Intrinziq Estimates Fair Value

Intrinziq estimates Can-Fite BioPharma Ltd.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Can-Fite BioPharma Ltd.Healthcare

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.